Final Results
Download
The full results are available to
download in PDF format
Operational Highlights:
Continued progress with major partners utilising Haydale's nanomaterial plasma functionalisation technology:
- Saint Gobain are now taking a Haydale plasma functionalised boron nitride product to market under the brand AdaptiflexTM;
- Underfloor heating application is now being trialled through a number of commercial partners who can provide channels to market in both the new build and retrofit housing market;
- Next stages of water heater projects commissioned by Cadent to progress towards a market ready product;
- Work with Petronas continuing with positive progress across a number of project initiatives that could ultimately lead to significant volume contracts
US operations continued to progress with its diversification into advanced cutting tool manufacture and distribution:
- Sales infrastructure strengthened in both the US through manufacture represeting networks and overseas with strategic white labelling partnerships in both Europe and China;
- Development of a one-stop-shop offering to customers through sourcing of other complementary tooling to supplement the core Silicon Carbide offering;
- Whilst the Company has developed a sizeable pipeline of opportunities which are starting to come through, the timescales to convert tooling opportunities into sales is continuing to take longer than originally anticipated.
Post year end and following the securing of an additional £3.1m of funding, a significantly reconstituted Board has embarked on a full and rigorous review of all aspects of the business with a view to reprioritising those areas offering up near term profit enhancement and positive cash generation, whilst continuing to pursue the most commercially attractive longer term strategic options. A key objective is to bring forwards the Group's break-even point compared to the current plan.
Financial Highlights
- Revenue at £4.82 million (FY23: £4.30 million) up by 12% on prior year underpinned predominantly by a 75% growth in UK revenues.
- Adjusted administrative expenses increased marginally by 1.4% to £6.35 million (FY23: £6.26 million).
- Adjusted operating loss improved slightly by £0.33 million to £3.16 million (FY23: £3.49 million).
- £3.1 million fundraising completed post period end.
Commenting on the results Gareth Kaminski-Cook, Executive Chair of Haydale, said:
"The Board recognises that progress has not proceeded with sufficient pace and therefore intends to use the recent fundraise as a catalyst for change. As noted above and in line with our commitment in the fundraise circular, the reconstituted Board has embarked on a thorough review including cost restructuring and commercial focus. Our priority is to bring forward the Group's break-even point and cash generation, and we will be reporting progress to the market in due course."
Chair's Statement
Introduction
I am pleased to present Haydale Graphene Industries Plc's ("Haydale", the "Group" or the "Company") full year audited results to 30 June 2024 ("FY24").
During the year the Company continued to focus its activities within its two key product areas, namely functionalised nano-materials and silicon carbide advanced tooling. Within each, focus has been absolute in terms of pursuit of projects capable of yielding commercial scale revenues for Haydale in the shortest possible timeframe. In the letter to shareholders at the time of the recent fundraising, we explained that because progress had been slower than anticipated, the reconstituted board would undertake a full and rigorous review of all aspects of the business with a view to reprioritising those areas offering up near term profit enhancement and positive cash generation, whilst continuing to pursue the most commercially attractive longer term strategic options. This review is now underway.
Summary financials
Commercial revenue for FY24 of £4.82 million (FY23: £4.30 million) was up by 12% on prior year with the UK nanomaterials business recording a 75% growth in sales. Gross profit margin was slightly up due to sales mix at 58% (FY23: 56%) resulting in a gross profit of £2.81 million (FY23: £2.39 million). Other operating income for the year of £0.38 million (FY23: £0.38 million) was in line with last year. Adjusted administrative expenses increased by £0.09 million (1.4%) to £6.35 million (FY23: £6.26 million) resulting in an adjusted operating loss of £3.16 million (FY23: £3.49 million). Total administrative expenses were £9.15 million (FY23: £8.93 million) as a result of the above plus a number of additional non-trading items, namely share-based payments charges of £0.03 million, depreciation and amortisation charges of £1.51 million and an impairment of US intangible assets of £1.23m. The loss for the year was £6.11 million (FY23: £6.17 million).
Operational Highlights
The UK operation saw the business partnerships fostered in FY23 develop positively, with new contracts secured with a number of high-profile blue-chip customers looking to use our plasma functionalisation service and technology to improve their own materials and end application performance. In addition, progress was made on our own heater ink and thermal transfer fluid products with an expectation that, in conjunction with our partners, some of these may be market ready early next financial year if not before, across a number of end applications.
The US operations have seen a period of retrenchment whilst infrastructure supporting the move up the value chain from SiC powders and into cutting tool manufacture and distribution has continued to be rolled out. The sales function has been strengthened which has materially increased the pipeline of opportunities albeit the sales cycle is proving to be longer than anticipated. Crucially, the US has signed a number of key agreements that significantly extend both the tool range it can offer to its customers as well as increase its geographical reach into Europe and Asia.
Staff
I would like to thank our staff for their outstanding support and commitment, as their efforts are key to our achieving our aims. I would also like to thank the executive management team who continue to drive the transition towards a sustainable commercial operation.
Funding
On 14 November 2024, the Company completed a fundraising of £3.1million (gross) and I would like to welcome our new shareholders and to thank our existing shareholders for their continued support.
Outlook
The Company recognises that progress has not proceeded with sufficient pace and therefore intends to use the recent fundraise as a catalyst for change. As noted above and in line with our commitment in the fundraise circular, the reconstituted Board has embarked on a thorough review (the "Review"), including cost restructuring and commercial focus. Our priority is to bring forwards the Group's break-even point and cash generation, and we will be reporting progress to the market in due course.
Gareth Kaminski-Cook
Chair
29 November 2024
STRATEGIC REPORT
FY24 has seen the UK operations, primarily focused on nanomaterials, increase its revenues by 75% on the back of a growing customer portfolio interested in its nanomaterial functionalisation services with material progress also made in the commercialisation of products based particularly on the Group's heating and cooling related IP. Of particular note, the Group is now engaged in collaborations with an increasing number of large multinational entities, all of which have the potential to lead to significant longer-term revenues. US operations, focused on advanced cutting tools, were strongly underpinned by SiC powder sales whilst the roll-out of the fundamental infrastructure to deliver the planned growth in SiC tooling manufacture and distribution continued apace, albeit the forecast growth in tooling sales has taken longer to manifest than expected. Across the Group, turnover increased by 12%: the third year in a row for growth whilst maintaining a gross margin in excess of 50%.
Nanomaterials
The UK operations continued to make significant progress over the year in progressing commercialisation of its proprietary technology resulting in a 75% increase in UK revenues overall, driven by a 190% growth in UK service type revenues. A number of new commercial programmes have been signed with larger, blue chip profile customers over the last half of FY24 and first quarter of FY25 for functionalisation services that have the potential to lead on to significant volume sales subject to product enhancement targets being achieved.
Patented Plasma Functionalisation Technology
At the core of all our product offerings and underpinning the Group's future nanomaterial prospects, is Haydale's patented HDPlas® plasma functionalisation process which improves the dispersibility of many nanomaterials by changing their surface chemistry using a highly tuneable, repeatable process. Plasma functionalisation allows Haydale to tailor advanced materials to enhance the properties of its customers' products to achieve pre-agreed mechanical or conductive performance criteria. The process is cost effective and environmentally friendly. Specifically, we have the expertise to:
- functionalise nanomaterials that are blended with resins, composites and fluids to deliver enhanced electrical, mechanical (strength) and thermal performance;
- formulate proprietary nanomaterial-based inks for the print and sensor markets, including biomedical, RFID and piezo resistive inks and sensors; and
- compound functionalised nanomaterials into a range of elastomers to enable customers to use nanomaterials in elastomeric products.
The Group safeguards its nanomaterials business across its sites and the territories in which it operates through the use of patents and trade secret protocols which protect its intellectual property. It holds licences where that intellectual property is for operational reasons with a third party. Haydale currently has a portfolio of patents that are variously recognised in the following territories - US, UK, Europe, China, Japan and Australia. Haydale works closely with its patent advisors, Mewburn Ellis LLP, and maintains a rolling programme of patent applications.
Plasma Functionalisation as a Service
We continue to secure commercial contracts with third party companies to plasma functionalise nanomaterial powders sourced by ourselves or provided by the customer which can then be delivered as powders, inks, masterbatches or pre-preg formats to meet the client's production requirements. These engagements normally start out as paid for consultancy projects where we are given performance targets that the functionalised material needs to meet and we work with the customer in an iterative fashion to fine-tune the various production related levers until the output targets are met or exceeded. The aim is to secure long term supply agreements for the toll manufacturing of the final plasma functionalised products, and for the larger customers, to lease reactors that can be deployed lineside and receive a throughput based royalty.
Customers include graphene manufacturers, who through the HDPlas® process, are able, post production, to extend the range of applications for which their product is suitable. We also have customers who have an end use materials improvement focus and require Haydale to source the best nanomaterial for the application. One major development during FY24 is the higher profile and larger size of customers we are now seeing approach us for this service as the use of graphene is filtering into the market at increasing pace (one study estimates that the graphene market is set to grow from £570m in FY24 to £5.2bn by 2032, a CAGR of 31.8%). These customers interactions mean we are indirectly involved in some of the largest growing sectors of the nanomaterial market including batteries, concrete, composites and tyres. Examples include:
- Saint Gobain, the French industrial conglomerate, have worked with us since April 2023 to develop their boron nitride powders to be competitive in new markets and in August 2024 launched a new product to the market (Adaptiflex™ Boron Nitride Powders) which is enhanced using our plasma functionalisation process, which we toll manufacture to their order.
- Petronas, the petrochemical giant, continues to work with us on a number of parallel projects to primarily help them take their own graphene product, refined from a byproduct of their main petrochemical business, and functionalise it so it potentially can be recycled into other applications.
- Vittoria are a leading performance bicycle tyre manufacturer with whom we have developed a graphene enhanced elastomer used in their premium tyres.
Plasma Functionalised Products Sales:
Heating
Geopolitical events and the UK Government's net zero strategy continue to bring an impetus for solutions in the energy efficient heating space, where Haydale has been active for a number of years initially with its range of off-the-shelf flexible graphene-based functional heater inks that can be printed roll-to-roll and onto a wide variety of substrates.
Using those heater inks, and in partnership with a number of leading firms, we have made significant strides in the development of a number of prototype low power heating applications that can operate from a battery and some of which are in the final stages of development, the main ones being:
- Underfloor heating: The prototype graphene-based heater sheets can now be printed roll to roll and then cut to size, so they can easily be rolled out under the flooring surface and connected to a DC supply. We were granted a UK patent for this innovation during the year. We are working with a number of partners to commercialise the ink and underfloor heating product, including Staircraft, part of Travis Perkins Plc, that fit flooring for many of the major UK house builders. Separately, we have concluded an agreement to trial our own underfloor heating solution via a social housing provider in the Channel Islands.
- Portable hot water & portable radiators: Having taken both the battery powered portable hot water unit and radiator to prototype stage, Cadent have now engaged and are paying us for the next phase to commercialise the prototypes so they can be deployed to their estimated 4 million vulnerable customers, to whom they have a legal requirement to support in off gas situations. With the freedom to take these products to the other energy utilities and into parallel leisure markets, we believe this represents a significant growth opportunity.
In FY23 we noted that we had developed our own graphene based thermal transfer fluid for use in heating and cooling systems that gives a much enhanced performance compared with existing fluids on the market, for which we have since been granted a UK patent. Work performed with Hydratech, a specialist heating fluid engineering firm, to finesse the formulation to work with the necessary additives is almost complete and we have now started the external validation process to verify the product meets applicable industry standards before being deployed, initially into Hydratech's customer base.
Sensors
We have a range of off-the-shelf functional inks appropriate for use in biomedical and other sensor applications that can potentially detect a wide range of medical conditions. These inks have a high sensitivity and are therefore able to replace lower grade carbon inks and potentially metallic based inks in existing sensor products. Our work with a leader in the glucose monitoring and diabetes management sector, whilst testing successfully, has had a hiatus due to internal reorganisations within the customer. We have however sold some product in the market and have other potential routes for this product, including China. We continue to work on other sensors including chlorine.
Composites
Our Thermal Tooling product is currently being tested at several UK OEMs in the Automotive and Aerospace sectors. We are also engaged with a major international defence company on graphene enhanced composite materials.
Focused research and development
We continue to work on customer-paid and grant-funded projects to develop plasma functionalised nanomaterial solutions where there is a clear problem statement and we believe there to be a volume demand at the end of the process for any product created. We are selective and, before proceeding, require a clear business case that results in a requirement for plasma functionalised material for third party applications or intellectual property that vests in Haydale. Grant funded work has resulted in new patents being granted in the UK for the graphene based underfloor heating and thermal transfer fluid products which both have large accessible markets.
Asia Pacific
The performance of the Asian operations was disappointingly at the lower end of expectation and their future will form part of the Review.
Silicon Carbide powders and tooling
SiC advanced cutting tools used to cut very hard metals is, in itself, a $957m global market and sits at the premium end of the industrial cutting tool markets. We understand that Haydale are one of only two US based manufacturers of the SiC whisker that is required to manufacture these tools. In addition, there are a range of other lower grade advanced cutting tools used for complementary tasks such as roughing and finishing, including Cubic Boron Nitride (CBN), Cermets and Carbide based tools, each of which have their own sizeable markets.
As reported last financial year, in FY23 Haydale established the tooling sales infrastructure to sell within the US through the establishment of a manufacturer representative network and tooling catalogue. During FY24, these initiatives have been supplemented by the implementation of a MRP system and a tooling sales orientated website to properly support the US sales function. The Company has also taken steps to reinforce the Manufacturer Representative network.
However, the major change in FY24 has seen Haydale take the necessary steps to ensure that it maximises its ability to capture market share by both increasing its reach into markets outside of the US and extending the range of advanced cutting tools it can offer customers as a one stop shop thereby better able to entirely displace competitors from accounts. The key actions taken were twofold:
Ø Extend the territories serviced by Haydale beyond North America:
o White label distribution agreement with a major European player signed covering UK and Eire which has led to some sizeable accounts being secured in FY24H2 and the arrangement being extended to cover the EU with discussions also ongoing in respect to the USA;
o White label manufacturing and distribution agreement signed in Q1 of FY25 for distribution of SiC tooling into the China market which accounts for circa 22.5% of the global market;
Ø Extend the range of advanced cutting tooling that Haydale can offer to include CBN (itself a £1.3bn Global market), Cermets and Carbide through agreements with Asian partners signed in FY24 Q4 and FY25 Q1.
Whilst the SiC tooling business has seen increasing traction on the back of the steps taken and we are in or awaiting testing with a number of large company accounts, the timescales to convert opportunities into sales is taking longer than expected which resulted in revenues being lower than originally forecast. That said, there is a sizeable pipeline of opportunities which are being progressed. Given the commodity nature of the products and the limited number of suppliers, the sales process is believed to be relatively straightforward being largely determined on price and tool life/performance. Haydale scores highly on both measures.
Haydale's traditional SiC powder business performed well over FY24 with significant sales to its repeat customer base, however this will likely mean that FY25 powder sales will be more subdued. SiC stock is usually manufactured on a two year cycle and to ensure that we maintain adequate stock levels, the production line and furnaces were turned on in June 2024 for a four month campaign which concluded at the end of September.
Other products
There continues to be interest in CeramycGuard™, a one stop solution to significantly extend the surface life of concrete assets utilising Haydale's SiC powder and for which Haydale holds the distribution rights for the UK market. The product is currently undergoing tests on the Thames flood defences with the Environmental Agency which, if successful, could result in a material supply contract.
Production Capacity
Haydale's FY22 investment in production capacity for its plasma functionalisation process and ink production means it has sufficient capacity to meet its forecasts for the next few years. Should additional capacity be required, Haydale has a scaling plan to affordably and materially increase its own internal capacity on relatively short timescales or, depending on anticipated volumes, arrange for a machine to be leased to a customer and charge a volume based royalty.
Likewise, there is also more than sufficient capacity for the manufacture of SiC powder in the US to meet the business plan for the next few years. Arrangements have been made to secure additional external tooling manufacturing capacity to support the planned short term growth.
Overheads
There have been some large inflationary pressures in certain areas of the cost base over the financial year. Whilst we have kept a tight lid on recruitment during FY24, due to the growth seen in the UK, we have had to strengthen certain functions towards the end of FY24 and early FY25. Likewise in the US, with the infrastructure now in place, we have had to make modest increases to the sales team to support growth.
At the same time, the Group has continued to take selective measures to reduce costs around the organisation and this will continue as part of the Review.
FUTURE STRATEGIC DIRECTION
As noted above, the US operations have potential for strong growth in the short term through the manufacture and sale of specialised SiC tooling and complementary products in all of the key global cutting tool markets. Having put the necessary infrastructure in place, the focus is now on managing the networks of US regional manufacturing representatives and distributors (both in the US and overseas) and supply chain to get the tooling into key end user sites.
On the nanomaterials front, we believe that with the size and nature of the customers that are coming to us, the potential for nanomaterials is increasing apace - however it is recognised that there is a significant time lag for these projects to progress into being commercial volumes. The focus for the UK continues to be on building business partnerships that will get its plasma functionalised nanomaterial solutions into the market, targeting customers that both recognise and are willing to share the commercial value such development process can provide either through the fee structure or sharing the downstream benefits in a more equitable way. It is further believed that certain of our own strategic products, primarily underfloor heating, can provide a quick route to revenue at scale and securing the necessary accreditations, commercial relationships and distribution channels will be fundamental to this.
Whilst the opportunity for Haydale's technologies as outlined above are compelling, the Directors are mindful that the Company has to be more focused in the allocation of resources towards the most profitable and cash generative near term opportunities.
FINANCIAL REVIEW
Statement of Comprehensive Income
In the year under review, the Group's principal areas of income were sales of specialty inks, fluids and graphene enhanced composites and associated consultancy services from the UK and APAC operations and sale of SiC fibres, whiskers, particulate, blanks and tooling from the US operation. The Group's revenue for the year ended 30 June 2024 of £4.82 million (FY23: £4.30 million) represents a 12% increase compared with the previous year. Revenue derived from product sales was consistent with prior year.
The Group's Gross Profit, which excludes Other Operating Income, was £2.81 million (FY23: £2.39 million) delivering a Gross Profit margin of 58% (FY23: 56%) which is slightly higher due to sales mix.
Other operating income, which is principally grant funded projects, was £0.38 million (FY23: £0.38 million) consistent with prior year.
Adjusted administrative expenses increased by £0.09 million (1.4%) to £6.35million (FY23: £6.26 million) reflecting inflationary rises partially offset by cost savings resulting in an adjusted operating loss of £3.16 million (FY23: £3.49 million). Total administrative expenses for the year were £9.17 million (FY23: £8.93 million) which, in addition to the above, reflects a significant reduction in non-cash related share-based payment expenses of £0.56 million primarily related to the expiry of the FY22 warrants. FY24 total administrative expenses also included a non-cash charge of £1.23 million related to an impairment of the historic intangible assets associated with the US powders business (FY23: £0.53 million relating to an impairment of fixed assets held in the US).
The Loss from Operations was £5.96 million (FY23: £6.17 million). Finance costs, which include interest payable on the Group's debt, for the year were £0.39 million (FY23: £0.41 million).
The Group continued to direct resources to research and development with the focus for that investment on products and processes that could develop into sustainable and profitable revenue streams. R&D spend for the year was £1.39 million1 (FY23: £1.52 million[1]), of which £0.50 million was capitalised (FY23: £0.42 million). During the year the Group claimed R&D tax credits of £0.24 million (FY23: £0.40 million) which has largely reduced due to changes in the scheme and it is expected that this claim will be received during the current financial year.
Total comprehensive loss for the year, was £5.80 million (FY23: £5.80 million) which in FY24 included £1.23 million (FY23: £0.53m related to tangible assets) of one off charges relating to impairment of intangible assets.
The loss per share for the year was 0.4 pence (FY23: 0.8 pence).
Statement of Financial Position and Cashflows
As at 30 June 2024, net assets amounted to £5.68 million (2023: £6.97 million), including cash balances of £1.72 million (2023: £1.38 million). Other current assets marginally increased to £3.39 million at the year-end (2023: £3.15 million) with modest reductions across most areas offset by an increase in trade debtors of £0.52 million reflecting a large year end sale in the US. Current liabilities increased slightly to £2.38 million (2023: £2.01 million) principally due to an increase in trade and other payables.
The Right of Use Asset in respect of its leased assets decreased to £1.79 million (FY23: £2.20 million) due to the continuing run out of lease agreements and reduction in the number of discrete property leases as part of planned cost savings. The Lease Liability, which is split between Current and Non-Current Liabilities, similarly decreased to £2.01 million (FY23: £2.44 million) as a result of the lease payments made throughout the year. The Company will amortise these balances over the remaining life of the leases which varies across the sites.
The Group's US Pension Obligations of £0.30 million (FY23: £0.58 million) has reduced in the year due to a combination of positive movements on investments, exchange and discount rate movements and contributions made.
Net cash outflow from operating activities before working capital movements for the year reduced to £3.35 million (FY23: £3.67 million), the principal contributing factors being the Loss after Taxation of £6.11 million (FY23: £6.17 million). Cash used in Operations decreased by £0.73 million in the year to £3.36 million (FY23: £4.09 million). The Group received an R&D tax credit inflow of £0.40 million in the year (FY23: £0.43 million). Net cash used in operating activities decreased to £2.96 million (FY23 £3.66 million).
Capital expenditure in the year, excluding the IFRS 16 adjustments, was £0.02 million (FY23: £0.20 million). The Group invested in a scanning electron microscope, acquired under lease arrangements, for the nanomaterial business, to be able to bring certain analysis services in house to improve quality control and reduce time taken to meet customer requirements.
Capital Structure and Funding
At 30 June 2024 the Company had 1,798,462,051 ordinary shares in issue (2023: 785,852,475). No options were exercised into ordinary shares during the year (FY23: Nil).
The Group's total borrowings at the year-end were £1.41 million (2023: £1.37 million), of which £1.23 million was in the UK and the balance in the Group's US subsidiaries. The UKRI Innovation loan has a quarterly liquidity covenant with which the Group has been in full compliance through the reporting period. There are no financial covenants extant in respect of the UK bounce back loan of £0.02 million (FY23: £0.03 million) or the Group's US borrowings.
Post Balance Sheet Event
On 14 November 2024, the Company raised £3.1 million (gross) through a £2.6m placing, retail offer and subscription of 1,960,633,907 new Ordinary Shares at 0.1326 pence per share and the issue of a £500,000 convertible loan note with a 10% coupon and 5 year tenor. The funds raised will be principally used to fund the general working capital needs of the business. As part of this process, the Company's share capital was restructured to in effect reduce the nominal value of each ordinary share from 0.1 pence to 0.01 pence.
Key Performance Indicators
The Group has historically reported financial metrics of revenues, gross profit margin, adjusted operating loss, cash position and other metrics as its key performance indicators and these are set out below.
FY24 (£m) | FY23 (£m) | |
Revenue | 4.82 | 4.30 |
Gross profit margin | 58% | 56% |
Adjusted operating loss | (3.16) | (3.49) |
Cash position | 1.72 | 1.38 |
Borrowings | 1.41 | 1.37 |
During the year under review, management also used a UK sales tracker, as a non-financial performance metric, to monitor the revenue pipeline of the business. The sales tracker monitors the number of accredited leads and assigns a probability of revenue realisation to those leads. For the US business, specific tooling related pipeline analysis has also been introduced to monitor the health and progress of opportunities through the sales funnel.
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the year ended 30 June 2024
| Note | Year ended 30 June 2024 £'000 | Year ended 30 June 2023 £'000 | ||
REVENUE | 3 | 4,820 | 4,301 | ||
Cost of sales | (2,008) | (1,911) | |||
Gross profit |
|
| 2,812 | 2,390 | |
Other operating income | 376 | 377 | |||
Adjusted administrative expenses | (6,346) | (6,260) | |||
Adjusted operating loss | (3,158) | (3,493) | |||
Adjusting administrative items: | |||||
Share based payment expense | (25) | (589) | |||
Depreciation and amortisation | (1,514) | (1,552) | |||
Restructure costs | (34) | (531) | |||
Impairment | (1,227) | (2,672) | |||
(2,800) | (2,672) | ||||
Total administrative expenses | (9,146) | (8,932) | |||
LOSS FROM OPERATIONS | (5,958) | (6,165) | |||
Finance costs | (393) | (407) | |||
LOSS BEFORE TAXATION | 4 | (6,351) | (6,572) | ||
Taxation | 241 | 407 | |||
LOSS FOR THE YEAR FROM CONTINUING OPERATIONS | (6,110) | (6,165) | |||
Other comprehensive income: |
|
| |||
Items that may be reclassified to profit or loss: | |||||
Exchange differences on translation of foreign operations | 52 | (341) | |||
Items that will not be reclassified to profit or loss: | |||||
Remeasurements of defined benefit pension schemes | 261 | 702 | |||
TOTAL COMPREHENSIVE LOSS FOR THE YEAR FROM CONTINUING OPERATIONS | (5,797) | (5,804) | |||
Loss for the year attributable to: | |||||
Owners of the parent | (6,110) | (6,165) | |||
Total comprehensive loss attributable to: | |||||
Owners of the parent | (5,797) | (5,804) | |||
Loss per share attributable to owners of the Parent | |||||
Basic (pence) | 5 | (0.40) | (0.80) | ||
Diluted (pence) | 5 | (0.40) | (0.80) | ||
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at 30 June 2024
Company Registration No. 07228939 | Note | 30 June 2024 £'000 | 30 June 2023 £'000 | |
ASSETS | ||||
Non-current assets | ||||
Goodwill | - | 1,059 | ||
Intangible assets | 1,338 | 1,386 | ||
Property, plant and equipment | 4,867 | 5,915 | ||
6,205 | 8,360 | |||
Current assets | ||||
Inventories | 1,670 | 1,733 | ||
Trade receivables | 1,088 | 564 | ||
Other receivables | 376 | 446 | ||
Corporation tax | 251 | 406 | ||
Cash and bank balances | 1,717 | 1,378 | ||
5,102 | 4,527 | |||
TOTAL ASSETS | 11,307 | 12,887 | ||
LIABILITIES | ||||
Non-current liabilities | ||||
Bank loans | 6 | (1,392) | (1,363) | |
Pension Obligation | (304) | (577) | ||
Other payables | (1,558) | (1,962) | ||
(3,254) | (3,902) | |||
Current liabilities | ||||
Bank loans | 6 | (14) | (11) | |
Trade and other payables | (2,186) | (1,899) | ||
Deferred income | (178) | (103) | ||
(2,378) | (2,013) | |||
TOTAL LIABILITIES | (5,632) | (5,915) | ||
TOTAL NET ASSETS | 5,675 | 6,972 | ||
EQUITY | ||||
Capital and reserves attributable to equity holders of the parent | ||||
Share capital | 16,730 | 15,717 | ||
Share premium account | 35,374 | 31,912 | ||
Share-based payment reserve | 408 | 833 | ||
Foreign exchange reserve | (301) | (353) | ||
Retained losses | (46,536) | (41,137) | ||
TOTAL EQUITY | 5,675 | 6,972 | ||
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the year ended 30 June 2024
| Share capital £'000 | Share premium £'000 | Share-based payment reserve £'000 | Foreign Exchange Reserve £'000 | Retained losses £'000 | Total Equity £'000 |
At 30 June 2022 | 10,207 | 31,912 | 244 | (12) | (35,303) | 7,048 |
Comprehensive loss for the year | ||||||
Loss for the year | - | - | - | - | (6,165) | (6,165) |
Other comprehensive income/(loss) | - | - | - | (341) | 702 | 361 |
10,207 | 31,912 | 244 | (353) | (40,766) | 1,244 | |
Contributions by and distributions to owners | ||||||
Recognition of share-based payments | - | - | 39 | - | - | 39 |
Share based payment charges - lapsed options | - | - | (45) | - | 45 | - |
Issue of ordinary share capital | 1,702 | 3,401 | - | - | - | 5,103 |
Transaction costs in respect of share issues | - | (309) | - | - | - | (309) |
At 30 June 2023 | 15,717 | 31,912 | 833 | (353) | (41,137) | 6,972 |
Comprehensive loss for the year | ||||||
Loss for the year | - | - | - | - | (6,110) | (6,110) |
Other comprehensive income/(loss) | - | - | - | 52 | 261 | 313 |
15,717 | 31,912 | 833 | (301) | (46,986) | 1,175 | |
Recognition of share-based payments | - | - | 25 | - | - | 25 |
Share based payment charges - lapsed warrants | - | - | (450) | - | 450 | - |
Issue of ordinary share capital | 1,013 | 4,050 | - | - | - | 5,063 |
Share issue cost | - | (588) | - | - | - | (588) |
At 30 June 2024 | 16,730 | 35,374 | 408 | (301) | (46,536) | 5,675 |
CONSOLIDATED STATEMENT OF CASH FLOWS
For the year ended 30 June 2024
Year ended 30 June 2024 £'000 | Year ended 30 June 2023 £'000 | ||||
Cash flow from operating activities | |||||
Loss after taxation | (6,110) | (6,165) | |||
Adjustments for:- | |||||
Amortisation and impairment of intangible assets | 1,614 | 335 | |||
Depreciation and impairment of property, plant and equipment | 1,128 | 1,747 | |||
Share-based payment charge | 25 | 589 | |||
Finance costs | 393 | 407 | |||
Pension: employer contribution | (161) | (180) | |||
Taxation | (241) | (407) | |||
Operating cash flow before working capital changes | (3,352) | (3,674) | |||
Decrease/(increase) in inventories | 63 | (218) | |||
(Increase)/decrease in trade and other receivables | (454) | 304 | |||
Increase/(decrease) in payables and deferred income | 383 | (503) | |||
Cash used in operations | (3,360) | (4,091) | |||
Income tax received | 397 | 427 | |||
Net cash used in operating activities | (2,963) | (3,664) | |||
Cash flow used in investing activities | |||||
Purchase of plant and equipment | (16) | (203) | |||
Purchase of intangible assets | (503) | (421) | |||
Net cash used in investing activities | (519) | (624) | |||
Cash flow from financing activities | |||||
Finance costs | (174) | (209) | |||
Finance costs - lease liability | (95) | (116) | |||
Payment of lease liability | 42 | (261) | |||
Proceeds from issue of share capital | (446) | 5,510 | |||
Share capital issues costs | 5,063 | (371) | |||
New bank loans raised | (588) | - | |||
Repayments of borrowings | (10) | (53) | |||
Net cash flow from financing activities | 3,792 | 4,500 | |||
Net increase in cash and cash equivalents | 310 | 212 | |||
Effects of exchange rates changes | 29 | (20) | |||
Cash and cash equivalents at beginning of the financial year | 1,378 | 1,186 | |||
Cash and cash equivalents at end of the financial year | 1,717 | 1,378 | |||